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Introduction: Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive
soft tissue sarcomas in which complete surgical resection is the mainstay of therapy. How-
ever, the recurrence rate is high and few options remain for refractory or metastatic MPNST.
This study examines the outcomes of adjuvant radiation therapy in MPNST in patients with
and without neurofibromatosis type 1 (NF1) and reviews the literature on use of radiation
for MPNST.
Methods: A retrospective review of 33 MPNST patients between 1990 and 2012 evaluated
at the NIH. All diagnoses were pathologically confirmed at the NCI. Clinical presentation,
treatment, and survival were analyzed.
Results:Thirty-three patients were included 18 NF1-associated, 15 sporadic tumors.Tumor
location included extremity (58%), trunk (36%), and head/neck (6%). Histologic grade
showed 25 high-grade tumors compared to 7 low-grade tumors. Twenty patients were
treated with radiation therapy (median total dose of 58.5 Gy with 1.8 Gy/fraction). A median
survival of all patients was 46.5 months and 43.7% overall 5-year survival. Prognostic fac-
tors include extent of resection, tumor location, and histology grade. Radiation was not
found to be a prognostic factor for overall survival.
Conclusion: This study is consistent with previous studies regarding the role of radiation
in the management of MPNST. Prospective evaluation of adjuvant radiation will allow to
more fully define the role of radiation in MPNST.
Keywords: malignant peripheral nerve sheath tumor, malignant schwannoma, neurofibrosarcoma, neurogenic
sarcoma, radiation therapy
INTRODUCTION
Malignant peripheral nerve sheath tumors (MPNSTs), also known
as malignant schwannomas, neurofibrosarcomas, and neurogenic
sarcomas, are rare, highly aggressive malignancies that arise from
major or minor peripheral nerve branches or sheaths. They
account for about 10% of soft tissue sarcomas (1, 2). More
than half of these malignancies arise in individuals with neu-
rofibromatosis type 1 (NF1). The majority of NF1-associated
MPNSTs arise from preexisting plexiform neurofibromas. The
lifetime incidence of MPNSTs in NF1 patients is 8–13% whereas
the general population has an incidence of 0.01% (1, 3–8). Sev-
eral studies have shown that patients with NF1-associated tumors
have a worse disease specific survival compared with sporadic
tumors (1, 3, 9–12).
Complete surgical resection of MPNSTs is required for cure.
Even with aggressive surgery and negative surgical margins,
local and distant recurrence occurs frequently. Radiation and
chemotherapy are additional modalities that are used to treat these
tumors. However, poor response to standard sarcoma chemother-
apy has been described for NF1-associated MPNST (1, 13). Despite
current multimodality therapy, the 5-year survival ranges from 35
to 50% (1, 3, 6, 7). The role of radiation therapy in MPNST is still
in evolution. Many studies have recommended the use of radiation
therapy in an adjuvant setting (1, 3, 4, 10, 11, 14–19). Yet, only one
study, to date, has shown a statistically significant increased local
control with radiation therapy (10). Thus, the primary goal of this
study was to examine the role and utility of adjuvant radiation
therapy in patients evaluated at the NCI for sporadic and NF1-
associated MPNST. A secondary goal was to review the literature
of the use of radiation therapy in MPNST.
MATERIALS AND METHODS
Medical records of patients evaluated at the National Cancer Insti-
tute between January 1990 and June 2012 for potential diagnosis
of MPNST were retrieved. For inclusion in this study, MPNST his-
tological diagnosis was confirmed by a NCI pathologist. This was
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approved by the office of human subjects research protection as a
retrospective analysis.
Malignant peripheral nerve sheath tumors were categorized as
NF1-associated in patients with a clinical diagnosis of NF1 using
consensus criteria or sporadic in the absence of a diagnosis of
NF1 (20). Clinicopathologic data collected included age at initial
diagnosis, gender, tumor location, tumor size, presence of metas-
tases, extent of resection, histology grade, immunohistochemical
staining for S100, and vimentin, neoadjuvant, and/or adjuvant
chemotherapy, and/or radiation. Histology grade was defined as
low or high grade. Low-grade referred to as grade I and high as
grade II and III (21). Tumor location were defined as extrem-
ity (upper and lower), trunk (chest wall, proximal groin, thorax,
abdomen, and retroperitoneum), or head and neck. Extent of
resection were defined as R0 (negative margins), R1 (microscopi-
cally positive), and R2 (macroscopically positive) as defined in the
pathology and surgical reports.
Radiation was defined as a treatment with curative intent. Radi-
ation dose, fractions, field size, treatment breaks, and toxicities,
resulting from radiation were also included. Acute toxicities were
judged by radiation therapy oncology group (RTOG) criteria.
Overall survival (OS), the time from diagnosis to death, and the
influence of clinicopathologic features on OS and local control was
analyzed using the Kaplan–Meier method and using the log-rank
(Mantel–Cox) test in the univariate setting. Statistical significance
was defined as p< 0.05.
A comprehensive review of the literature for treatment of
MPNST was conducted. The systematic literature search included
Cochrane Collaboration Library electronic database, PubMed,
RTOG.org, and ClinicalTrials.gov, using the following terms and
keywords: MPNST, NF1, neurofibrosarcoma, malignant schwan-
noma,radiation therapy,and a combination of these terms. Studies
were limited to those reported in the English language and human
subjects. Original studies were reviewed independently.
RESULTS
PATIENT AND TUMOR CHARACTERISTICS
Of the 56 patients evaluated for MPNST, 33 fulfilled criteria for
this study (Table 1). Most patients were excluded because there was
not enough data or follow up. NF1-associated MPNSTs (n= 18)
were more frequent than sporadic MPNSTs (n= 15). The median
overall age at diagnosis was 25 years (range 9–76 years). There was
a difference in median age between NF1 patients and sporadic,
15 and 41, respectively. Females constituted 33% (n= 11) of the
study. There were more males in the NF1 study group as compared
to the sporadic patients, 78 and 53%, respectively.
Most tumors presented as local disease but one patient in
each group presented with metastatic disease. NF1-associated
tumors were larger at the time of diagnosis, 438.4 cm3 (range:
64–4377cm3), whereas the sporadic tumor volume was 240.6 cm3
(range: 10–1000 cm3). MPNSTs were most commonly located in
the extremity (n= 19, 58%), followed by trunk (n= 12, 36%),
and least commonly head and neck region (n= 2, 6%). Both
NF1-associated and sporadic tumors were most common in the
extremity, 61 and 53%, respectively.
Histologic grade of these tumors reported that high-grade dis-
ease was more prevalent (n= 25). The presence of necrosis was
Table 1 | Patient characteristics.
Characteristics NF1 (n=18) Sporadic (n=15)
Median age (years) 15 41
Gender
Female 4 (22%) 7 (47%)
Male 14 (78%) 8 (53%)
Presentation
Local 17 (94%) 14 (93%)
Metastatic 1 (6%) 1 (7%)
Tumor size (cm3) 931.4 275.6
Location of tumor
Head/neck – 2 (13%)
Trunk 7 (39%) 5 (33%)
Extremity 11 (61%) 8 (53%)
Histology
Low grade 4 (22%) 3 (20%)
High grade 14 (83%) 11 (73%)
Presence of necrosis 9 (50%) 1 (7%)
S100
Positive 11 (61%) 10 (67%)
Negative 1 (6%) 2 (13%)
Vimentin
Positive 3 (17%) 8 (53%)
Negative 3 (17%) 2 (13%)
Extent of resection
R0 7 (39%) 6 (40%)
R1 4 (22%) 4 (27%)
R2 7 (39%) 5 (33%)
Neoadjuvant chemotherapy 2 (11%) 7 (47%)
Radiation 10 (56%) 10 (67%)
Treatment regimens
Surgery alone 4 (22%) 1 (6%)
Chemotherapy+ surgery 4 (22%) 4 (27%)
Radiation+ surgery – 3 (20%)
Chemotherapy+ surgery+ radiation 10 (56%) 7 (47%)
seen in nine patients with NF1 (50%) and one patients with
sporadic tumors (7%). S100 positive staining was seen in 61%
of NF1 patients while sporadic tumors showed 67% positive
staining. Vimentin staining was positive in three patients with
NF-associated and eight patients with sporadic tumors.
The extent of resection was similar in both groups. Nega-
tive surgical margins were achieved in 13 patients. R1 resection
was achieved in 8 patients and R2 resection in 12. A total of
9 patients were treated with neoadjuvant chemotherapy and 20
patients (61%) treated with radiation therapy. The most com-
monly used chemotherapy agents for these patients included
vincristine, adriamycin, cyclophosphamide, etoposide, docetaxel,
ifosfamide, cisplatin, and gemcitabine. Treatment regimens con-
sisted of surgery (n= 5), chemotherapy plus surgery (n= 8),
radiation plus surgery (n= 3), and chemotherapy, radiation, and
surgery (n= 17).
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Twenty patients were treated with radiation therapy (Table 2).
Modalities of radiation included external beam (n= 15),
brachytherapy (n= 2), proton therapy (n= 1), and external
beam plus brachytherapy (n= 2). NF1-associated tumors (n= 10)
received a median total dose of 59.4 Gy with a median of
1.8 Gy/fractions. Sporadic tumors in the adjuvant setting (n= 10)
received a median total dose of 58.5 Gy with a median of
1.8 Gy/fractions. Local control rates for NF-1 patients treated with
radiation were 51% at 5 years. Local control rates for patients
treated with radiation were 53% as compared to 45% in those not
treated with radiation at 5 years, which was not statistically signif-
icant. Patients were treated with a mix of IMRT and 3D conformal
using 6 MV. The field size of the tumor that was treated was sub-
stantially larger in NF1-associated tumors as compared to sporadic
tumors, 597.9 cc3 (range: 31.5–2325.1 cc3) and 290.9 cc3 (range:
18–486.5 cc3), respectively. One patient from each NF1-associated
and sporadic tumors required a treatment break during radiation.
RTOG acute grade I toxicities were reported in a total of eight
patients, three patients in the NF1 and five patients in the sporadic
groups. Toxicities included fatigue, nausea, mild dysphagia, mild
erythema, mild odynophagia, and desquamation. There were no
toxicities exceeding grade II. Secondary cancers occurred in three
patients including pilocytic astrocytoma, brain cancer (unspeci-
fied), and liver. Two of these patients had NF1 and the liver cancer
was in the field of radiation treatment.
SURVIVAL ANALYSIS
The median survival of all patients was 33 months and overall 5-
year survival was 43.7% (Table 3; Figure 1). In the NF1-associated
tumors, the OS was 22.1 months as compared to sporadic tumors
with a median of 64.3 months (p= 0.13) (Figure 2A). NF1-
associated tumors treated with radiation had a median survival of
33.1 months as compared to 17.4 months with those patients that
did not receive radiation treatment. Distant metastases accounted
for five patients (28%) in NF1-associated MPNST as compared to
seven patients in the sporadic MPNST (47%). Pulmonary metas-
tasis was seen in three patients (17%) in the NF1-associated and
seven patients (47%) in the sporadic MPNST. Poor prognos-
tic factors that were statistically significant included incomplete
resection (p= 0.007) (Figure 2B), histologic grade (p= 0.04), and
truncal tumor location (p= 0.01) (Figure 2C). Radiation ther-
apy was not found to be a prognostic factor for OS (p= 0.97)
(Figure 2D).
LITERATURE REVIEW
The literature review identified 19 mostly retrospective studies
published since 1973 with patients treated starting in 1920 until
2011. The studies included 20–205 patients with 17–100% with
NF1. Tumor size as a prognostic factor for survival was significant
in 12 studies where larger tumors had a worse prognosis. NF1 was
regarded as a negative prognostic factor in seven studies. Age at
initial diagnosis, where younger age was a worse prognosis for sur-
vival, was significant for four studies and tumor location for nine
studies. Extent of resection was a prognostic factor in 14 studies,
where incomplete resection had a worse survival prognosis. Radi-
ation was a statistically significant local control prognostic factor
in one study (10), yet, there was a trend and recommendation for
Table 2 | Radiation characteristics.
Characteristics NF1 (n=10) Sporadic (n=10)
Type of radiation
External beam 7 (70%) 8 (80%)
Brachytherapy 1 (10%) 1 (10%)
Proton therapy 1 (10%) 0
External beam and brachytherapy 1 (10%) 1 (10%)
Adjuvant radiation
Fractions (median) 31 28
Dose/fraction (median) 1.8 Gy 1.8 Gy
Total dose (median) 59.4 Gy 58.5 Gy
Treatment volume (cc3) (mean) 438.4 240.6
Treatment breaks 1 1
RTOG acute grade toxicities 3 5
Table 3 | Survival of NF1 and sporadic MPNST.
Characteristics NF1 (n=18) Sporadic (n=15)
Overall survival (median) 22.1 months 64.3 months
Radiation 33.1 months 51.6 months
No radiation 17.4 months 69.4 months
Local failure 7 (39%) 5 (33%)
Distant failure 5 (28%) 7 (47%)
Pulmonary metastasis 3 (17%) 7 (47%)
FIGURE 1 | Overall survival of patients with MPNST.
radiation in seven reports. Overall of the 19 studies, 18–83% of
patients received radiation therapy treatment. Doses ranged from
12.5–90 Gy in these studies. As seen in the table, OS ranged from
16 to 65.7% (Table 4).
DISCUSSION
Malignant peripheral nerve sheath tumors are uncommon soft
tissue sarcomas. The prognosis for unresectable MPNST is poor.
There is a scarcity of data addressing radiation therapy as a local
www.frontiersin.org November 2014 | Volume 4 | Article 324 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kahn et al. Radiation therapy treatment of MPNST
FIGURE 2 | Overall survival of (A) NF1-associated MPNST compared with sporadic MPNST, p=0.13; (B) the extent of resection, p=0.007; (C) tumor
location, p=0.01; (D) radiation treatment versus no radiation treatment, p=0.97.
therapy. Our study provides a detailed analysis of the treatment
of patients with sporadic or NF1-associated MPNSTs as well as a
review of the literature.
The association between MPNST and NF1 has been docu-
mented extensively. Studies have shown that individuals with NF1
have a higher than expected frequency of MPNST (3, 9, 10, 14, 27).
This may be because patients with NF1 have a somatic mutation in
the NF1 tumor suppressor gene, which results in the development
of benign nerve sheath tumors called plexiform neurofibromas,
which are at risk for malignant degeneration (28). In many stud-
ies, the mean age of diagnosis of MPNST in these NF1 patients
is between 25 and 28 years old (2–4). As seen in the literature age
at diagnosis has also been a prognostic factor for some studies
including Wanebo et al. who found that there was reduced sur-
vival in patients younger than 30 years of age reflecting on the
aggressiveness in the younger population (4). Our study similarly
showed a median diagnosis of 15 years old. In sporadic tumors,
the mean age of diagnosis for patients has ranged from 39 to 60 in
studies (2–4). Our study likewise shows a median of 41 years old
for sporadic tumors.
Some studies have shown that NF1 was a poor prognostic factor
for survival statistically while others have shown a trend toward
sporadic tumors being a good prognostic indicator (1, 3, 9–12,
15, 18, 22). The 5-year survival rates of those with NF1-associated
tumors ranged from 16 to 60%, whereas in sporadic tumors the
rates ranged from 47 to 75% (1, 3, 9–11, 16, 22). At diagnosis, NF1-
associated MPNST tend to be large, invasive, and unresectable
(1). NF1-associated MPNSTs are commonly more frequent in the
trunk as compared to sporadic MPNST (6, 11), which affects out-
come because central lesions may be less amenable to surgery
than are extremity MPNSTs (3, 22). NF1-associated MPNSTs have
also been thought to have a greater tendency to metastasize than
sporadic MPNSTs. Ducatman et al. showed that of 62 patients
with NF1-associated MPNSTs, 39% developed metastatic disease
whereas only 16% of 58 sporadic MPNSTs developed metastases
(3). The diagnosis of MPNST in patients with NF1 is difficult to
establish clinically without biopsy because they are often mistaken
for neurofibromas and therefore present at a later stage (3, 15,
29). NF1-associated tumors had a 5-year OS of 32.2% as com-
pared with 53.8% in sporadic tumors. Although our data does not
show statistical significance (p= 0.13) for poor prognosis of NF1
patients our data does show a trend that sporadic patients have a
better prognosis. Our data correlate with these studies and suggest
that the need for expeditious evaluation in patients with NF1 with
rapidly growing lesions.
Tumor location has been hypothesized as a prognostic factor
because of the ability of complete surgical resection to be more
easily achieved in extremities versus tumors in the abdomen or
chest (3, 22). Primary tumors of the extremities are also thought
to be diagnosed earlier because the more visible location (10, 22).
Tumor location was found to be a prognostic factor in nine studies
with extremities having the better prognosis. The location of the
tumor was found to be a prognostic factor for survival in our study
(p= 0.01). Tumors located in the truncal region fared worse than
those with lesions in the extremities, which is consistent with the
literature.
Malignant peripheral nerve sheath tumors are locally aggres-
sive and failure to achieve local control remains the major cause
of treatment failure. Complete surgical resection is the only cura-
tive treatment for sporadic and NF1-associated MPNST (1). The
surgical goal is to resect the tumor with wide negative margins.
In our study as well as previous studies, incomplete resection and
negative margins have been shown to be statistically significant for
survival (1, 3, 4, 6, 7, 9–11, 14, 16–18, 23, 26). The results of this
study indicate that complete surgical removal of the tumor is the
mainstay of treatment and a strong predictor of survival.
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Table 4 | Previous studies on treatment of MPNSTs.
Reference Institution Dates No.
pts
NF1
(%)
Prognostic factors Radiation Overall survival (%)
NF1 Age Tumor
size
Tumor
location
Extent of
resection
Radiation No.
pts (%)
Dose
(Gy)
5 year 10 year 5 year
sporadic
5 year
NF1
(9) MSKCC 1920–1970 115 26 Y – – – Y – – – 65.7 58.2 75 30
(14) UCLA 1957–1977 20 70 N – – – Y T 50 30–60 40 – – –
(22) MSKCC 165 40 Y N N Y – – 39 – – 32 47 23
(3) Mayo Clinic 1912–1983 120 52 Y Y Y N Y N 49 – 34 22 53 16
(15) MKSCC 1945–1988 43 53 N – Y – – N 35 24–66.5 39 – 42 38
(4) U Virginia HC 1960–1990 28 54 N Y Y Y Y T 18 54–68 43.7 – – –
(2) Netherlands 1977–1990 22 50 N – – – – – 45 – 35 24 – –
(23) St. Jude’s 1964–1993 28 39 N N N Y Y T 46 – 39 – – –
(10) Mayo Clinic 1975–1993 134 24 Y – Y Y Y Y 54 7.5–90 52 34 57 36
(18) MKSCC 1960–1995 25 60 N N Y N Y – 44 20–59.4 16 16 12 20
(17) Italy 1976–1996 24 29 – – T – Y T 50 50–54 – – – –
(24) London 1987–1995 29 100 N N Y N N N 83 – 35 – – 35
(16) MGH 1991–2001 54 22 – Y Y Y Y N 69 – – – – –
(1) Italian and
German
1975–1998 167 17 Y Y Y Y Y T 63 45–70 51 43.4 55 32
(7) Milan, Italy 1976–2003 205 22 T N Y Y Y T 44 45–65 39.9 43.3 38.9 43.9
(25) Germany 1991–2003 52 73 Y N N Y N N – – – – – –
(6) MDACC 1986–2006 140 55 N – Y N Y – 49 50–56 38.7 26.4 42.3 34.8
(11) Mayo Clinic 1985–2010 175 32 Y – Y Y Y T 63 – 60 45 75 54
(26) MKSCC 1982–2011 105 40 N N Y N Y N 61 – 64 (3 years) – 66 (3 years) 60 (3 years)
Present
study
NCI 1990–2012 33 55 N N – Y Y T 60.6 42–70.2 43.7 – 53.8 32.2
T, trend toward yes but not statistically significant.
OS, overall survival.
Did not specify in paper.
Prognostic factors: NF1 (worse prognosis), age (younger worse prognosis), tumor location (extremities better prognosis), extent of resection (complete resection better prognosis), RT (Tx of radiation better
prognosis).
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Multidisciplinary evaluation of these patients is crucial in order
to provide optimal care. Numerous studies have not found radia-
tion therapy to be a prognostic factor for local control or survival
(1, 3, 4, 6–8, 11, 12, 15, 16, 18, 22–25). Yet, many studies have also
stated that the use of adjuvant therapy is expanding when patients
do not have clear surgical margins (1, 4, 7, 30). Although there
have been no prospective randomized trials of radiation therapy
in the context of MPNST, there have been studies of the role of
adjuvant radiation in adult soft tissue sarcomas (31, 32). Yang et al.
found that post-operative radiation therapy is highly effective in
local control in soft tissue sarcomas of the extremities (31). Wong
et al. found that the 5-year local control rates for radiation doses
higher than 60 Gy was 73% as compared with 50% for lower doses
(p< 0.021), showing that post-operative radiation therapy has a
role in improving local control (10, 17). Yet, in an updated study
of Stucky et al. with some of the patients from the Wong et al.
study as well as two more institutions, the analysis showed radia-
tion therapy not to be a prognostic factor for local control. It was
hypothesized that this may be because of an evolution of treatment
with an emphasis of achieving negative margins. Even so, Stucky
et al. encouraged that radiation therapy be utilized for tumors
that have aggressive features including size≥5 cm, high grade, and
R1 or R2 margin status (11). Our study similarly showed that the
patients treated with adjuvant radiation were not a prognostic fac-
tor for local control. This study should also take into account that
there is an inherent selection bias given the retrospective nature of
the study. Patients were likely selected for radiation therapy based
on more extensive tumors, margin status, and unresponsiveness to
other therapies, which would bias the results toward not showing
a benefit of radiotherapy. As evident by these studies, the role of
radiation therapy is still being defined.
In this series, we evaluated the effectiveness of radiation therapy
on survival in the setting of MPNST. Radiation therapy treatment
was not statistically significant for OS in our study. These data
are consistent with the literature where there is no MPNST study
that shows a statistically significant difference in OS for those with
radiation treatment. In a SEER analysis, high-grade tumors treated
with radiation did have improved survival where they looked at
142 patients with MPNST and grouped them with other soft tissue
sarcomas (33). Although there have not been studies only looking
at MPNSTs, this study would infer that high-grade soft tissue sarco-
mas, including MPNST, should be treated with radiation therapy.
Aggressive therapeutic approaches are important in patients at
high risk and every effort should be considered.
In our study, most patients treated with radiation received
external beam therapy while few patients received protons and
brachytherapy. In the adjuvant setting, the total radiation dose was
≥56 Gy. This is compared with previous studies, which have found
that a cumulative dose of≥60 Gy was required to provide local dis-
ease control (10, 32). Although very few patients were treated with
brachytherapy this modality was given as a boost to external beam
radiation. Previous studies have evaluates the use of brachytherapy
for soft tissue sarcomas and found it to be an effective treatment
in combination with external beam radiation in local control (34).
One study, in particular, found the use of brachytherapy or intra-
operative electron radiation therapy to be a prognostic factor for
local control with a 5-year local control of 88% in those treated
with brachytherapy and 51% in those treated with external beam
(10). Adjuvant external beam therapy in another study was found
to have better local control then brachytherapy (35). Only one
patient in our study received proton therapy and is alive without
evidence of disease. Even though there have been no studies on
proton beam therapy in MPNSTs this modality of treatment may
be a viable option for younger patients or to minimize toxicity.
CONCLUSION
In conclusion, our analysis shows that radiation therapy can be
effective in achieving local and symptomatic control with well-
tolerated toxicities. Prognostic factors for survival include tumor
location, histology, and extent of surgical resection. Our study is
limited by its retrospective nature, small sample size, and hetero-
geneity in the patient population analyzed and their treatment.
Prospective studies evaluating the effect of radiation therapy is
required. In the adjuvant setting, it will be imperative to assess the
dose and modality of treatment. The role of radiosensitizers and
other novel techniques should also be explored.
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